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ABSTRACT
Graft-versus-host disease (GVHD) is a serious complication of allogeneic stem cell transplantation for
hematologic diseases. Antigen mismatches due to polymorphic differences between the patient and donor are
central in the mechanisms of GVHD. Polymorphisms are known for FcRIIa, and this molecule is present on
endothelial, dendritic, and Langerhans cells. Donor cells reacting against the patient as GVHD can also react
against the malignancy of the patient, and this is known as the graft-versus-leukemia (GVL) effect. Because the
FcRIIa molecule is also present on acute myeloid leukemia (AML) cells, an FcRIIa mismatch could be a
target for both GVHD and GVL. We retrospectively studied 73 AML patients and analyzed the differences in
GVHD and relapse incidence between patients with and without a pro-GVHD/GVL FcRIIa allotype mis-
match. We observed a difference in FcRIIa receptors with a pro-GVHD/GVL mismatch in 18 patient/donor
pairs (25%). Univariate and multivariate analyses demonstrated the pro-GVHD mismatch to be a significant
risk factor for the development of acute GVHD. There was no effect on the occurrence of chronic GVHD. The
relapse incidence was not significantly different for patients with or without the pro-GVL mismatch, although
there was a trend for fewer relapses in standard-risk AML patients with the pro-GVL mismatch. We conclude
that the polymorphism of the FcRIIa receptor may be a candidate target for acute GVHD.
© 2005 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Major drawbacks of allogeneic stem cell transplan-
ation (SCT) for leukemia are graft-versus-host dis-
ase (GVHD) and relapse. GVHD is a major immu-
ologic complication of SCT that involves donor T
ells and multiple cellular and cytokine effectors, but
t also favors the development of the beneﬁcial graft-
ersus-leukemia (GVL) effect [1,2]. It is still unclear
hether GVHD and GVL are 2 different reactions or
re exerting their effects through the same mecha-
ism(s) [3]. In HLA-identical SCT, allogeneic T-cell
esponses are directed against minor histocompatibil-
ty antigens (mHa) [4-6]. Minor histocompatibility
ntigens are deﬁned as polymorphic molecules that
an stimulate T-cell responses. They may represent p
06eukemic or hematopoietic antigens that can be targets
or donor T cells active in GVL or may represent
issue-speciﬁc antigens that can be targets for donor T
ells active in GVHD. In allogeneic SCT, genetic
actors, such as cytokine or adhesion molecule gene
olymorphisms, have been reported to modify the
ncidence and severity of GVHD [7-10]. These factors
ight also be targets for donor T cells active in GVL.
FcR expressed on leukocytes constitute a heteroge-
eous family of membrane-bound proteins. There are 3
eukocyte receptors for human immunoglobulin G:
cRI (CD64), FcRII (CD32), and FcRIII (CD16).
he various FcR (sub)classes of this family differ in
igand afﬁnity and speciﬁcity, which is determined by
rimary structure, glycosylation, association with signal-
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FcRIIa as Target for Acute GVHD in Allogeneic SCT
Bng subunits, environmental factors (such as serine pro-
eases), and polymorphic differences [11-13]. A geneti-
ally determined polymorphism has been described for
eukocyte FcRIIa. The different FcRIIa allotypes dif-
er by a single amino acid within the second immuno-
lobulin-like domain: either an arginine or a histidine at
osition 131 (FcRIIa-R131 or FcRIIa-H131) [11-13].
he FcRIIa-R/R131 and -R/H131 allotypes have a
istribution of 70% in Caucasians, whereas the FcRIIa-
/H131 allotype has a distribution of 30% [14-16].
Polymorphisms of FcRIIa critically affect interac-
ion with antibodies and are now considered risk factors
or a number of infectious and autoimmune diseases
11,17,18]. FcRIIa is a surface receptor of granulocytes
neutrophils, basophils, and eosinophils), monocytes,
acrophages, dendritic cells, platelets, T cells, Langer-
ans cells, and endothelial cells that reacts with the Fc
egion of immunoglobulin G [11-13,19,20]. Polymor-
hic differences in FcRIIa could serve as a potential
arget for donor-derived T cells for GVHD and GVL,
ecause FcRIIa is expressed on endothelial cells, Lang-
rhans cells, dendritic cells, and almost all myeloid leu-
emic cells.
To investigate whether FcRIIa mismatches can
e targets for GVHD and GVL, we assessed the
ffect of FcRIIa donor/patient mismatches on the
ccurrence of GVHD and GVL, together with
ther recognized factors, by univariate and multi-
ariate analyses in 73 patients undergoing partially
cell–depleted allogeneic SCT for acute myeloid
eukemia (AML).
ATERIALS AND METHODS
atients and Allogeneic SCT
A cohort of 80 consecutive patients with AML
ho received a partial T cell–depleted allogeneic SCT
rom an HLA-matched donor between March 1992
nd August 2002 at the Department of Hematology,
niversity Medical Center Utrecht, were included in
his study. Patients had to survive at least 100 days
fter transplantation for inclusion. Patients with good-
isk AML—t(8;21), t(15;17), or inv(16)—did not un-
ergo transplantation in ﬁrst complete remission (CR)
nd are not included in this study. No DNA was
btained from 7 patients, so these patients were ex-
luded from the study (n  73). Fifty-seven patients
78%) underwent transplantation in ﬁrst CR, 5 pa-
ients (7%) in CR2, 7 patients (10%) in relapse, and 4
atients (5%) in partial remission (50% reduction of
lasts in a marrow biopsy showing normal cellularity
nd without blasts in the peripheral blood). Standard-
isk AML (n  47) was deﬁned as patients who un-
erwent transplantation in CR1 and had no high-risk
eatures: ie, del(5q)/5, del(7q)/7, abnormality 3q,
nd complex (3 different) karyotypes. High-risk
B&MTML (n  26) was deﬁned as patients who underwent
ransplantation in relapse, CR2, or partial remission;
ad the previously mentioned high-risk features; or
ad secondary AML. The characteristics of the pa-
ients are shown in Table 1. All patients were treated
ith protocols approved by the local investigational
eview board and gave informed consent.
Donor bone marrow cells were collected in 53
ases (bone marrow transplants; BMT), and 20 pa-
ients received peripheral blood stem cells (peripheral
lood stem cell transplants; PBSCT) from the donor.
fter maximal T-cell depletion, the number of T cells
n the graft was counted, and the required number of
cells (set apart at the start of the manipulation
rocedure) were reinfused to the graft to obtain the
xed number of 1 to 2  105 T cells per kilogram of
ody weight in the graft, as described previously [21].
able 1. Characteristics of All Patients (n  73)*
Variable Data
ex, n (%)
Male 33 (45%)
Female 40 (55%)
ex of recipient/donor, n (%)
M/M 19 (26%)
M/F 14 (19%)
F/F 11 (15%)
F/M 29 (40%)
ge of recipient, y, median (range) 42 (19-62)
ge of donor, y, median (range) 46 (18-70)
iagnosis, n (%)
AML M0 3 (4%)
AML M1 11 (15%)
AML M2 30 (41%)
AML M4 15 (21%)
AML M5 13 (18%)
AML M7 1 (1%)
tage of transplantation
CR1 57 (78%)
CR2 5 (7%)
PR 4 (5%)
In relapse 7 (10%)
ype of allogeneic transplantation
BMT 37 (51%)
PBSCT 20 (27%)
MUD† 16 (22%)
isease stage
Standard risk 47 (64%)
High risk 26 (36%)
MV serology status (recipient/donor)
/ 16 (22%)
/ 15 (20%)
/ 13 (18%)
/ 29 (40%)
ear of transplantation
<1998 28 (38%)
>1998 45 (62%)
R indicates partial response.
Median number of T cells infused was 1 to 2  105 T cells per
kilogram of body weight. GVHD prophylaxis was cyclosporine.
HLA-A, -B, -C, -DRB1, and -DQB1 matched by high-resolution
molecular typing with sequence-speciﬁc primers from 1999 and
HLA-A, -B, -C, and -DRB1 matched by low-resolution molec-
ular typing with sequence-speciﬁc primers until 1999.
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2The conditioning regimen consisted of cyclophos-
hamide (60 mg/kg) infused on each of 2 successive days
ollowed by total body irradiation (12 Gy) in 2 fractions.
he 16 recipients of transplants frommatched unrelated
onors (MUDs) also received antithymocyte globulin
efore transplantation to enhance engraftment. All pa-
ients received a short course of cyclosporine, starting
ith 3mg/kg/d intravenously by continuous infusion the
ay before stem cell infusion and continuing for 28 days;
hereafter, it was given orally. Generally, cyclosporine
as stopped within 3 months after transplantation. Pa-
ients with grade II to IV acute GVHD were treated
ith prednisone 1mg/kg orally twice a day for at least 14
ays; thereafter, the prednisone dose was decreased and
as stopped, if possible, after 21 days. Chronic GVHD
as treated with systemic corticosteroids, sometimes
ombined with cyclosporine [22].
iagnosis and Evaluation of GVHD
Acute GVHD (grades I-IV) and chronic GVHD
limited or extensive) were diagnosed clinically, con-
rmed pathologically by skin biopsy, and classiﬁed
ccording to standard criteria [23]. Chronic GVHD
as deﬁned if GVHD was present after day 100.
cRIIa Genotyping
FcRIIa genotyping was performed on genomic
NA of patients and donors by using polymerase
hain reaction–based genotyping methods as de-
cribed previously [24]. In brief, 2 FcRIIa-speciﬁc
rimers were used to amplify a 1000–base pair frag-
ent of the FcRIIa gene containing the polymorphic
ite. Subsequently, the ampliﬁed fragments served as a
emplate to amplify a 278–base pair fragment in an
llele-speciﬁc primer reaction. In each experiment,
equence-veriﬁed genomic DNA of all 3 genotypes
as included as controls. Ampliﬁed products were
nalyzed by gel electrophoresis (1.5% agarose), sta-
ned with ethidium bromide, and visualized under
ltraviolet light.
tatistical Analyses
The pro-GVHD/GVL mismatch was deﬁned as a
ifference in FcRIIa allotype between patient and
onor that can cause GVHD or GVL: donor
cRIIa-R/R131 allotype with patient FcRIIa-R/
able 2. FcRlla Allotypes in Patient-Donor Combinations
Patient FcRlla-R/R131
cRlla-R/R131 13
cRlla-R/H131 6*
cRlla-H/H131 1*
otal 20Pro-GVHD/GVL mismatch.
08131 or -H/H131 allotype and donor FcRIIa-H/
131 allotype with patient FcRIIa-R/H131 or -R/
131 allotype (Table 2).
Univariate and multivariate analyses were used to
dentify independent risk factors for overall survival,
elapse incidence, and acute and chronic GVHD by
eans of Kaplan-Meier analysis and the Cox propor-
ional hazards model, respectively. Univariate analyses
ere performed with the log-rank test. In multivariate
nalyses, P values from regression models were calcu-
ated with the stepwise backward likelihood ratio, and
redictors were removed when P  .10. P values .05
ere considered signiﬁcant. Ten covariates were ana-
yzed: the pro-GVHD/GVL mismatch (yes or no),
ecipient age (40 and 40 years), disease status
standard risk versus high risk), type of allogeneic
ransplantation (allogeneic BMT, allogeneic PBSCT,
r allogeneic MUD), cytomegalovirus (CMV) serosta-
us (recipient/donor /, /, /, or /), sex
atch (male/female, male/male, female/male, female/
emale), acute GVHD (none versus grades I-IV),
hronic GVHD (none versus limited or extensive),
elapse (yes or no), and date of transplantation (before
998 or 1998 or later).
ESULTS
cRIIa Polymorphism
A difference in the FcRIIa polymorphism was
bserved for FcRIIa in 35 (48%) of the 73 patients.
n 18 patients (25%), this FcRIIa allotype difference
ad a pro-GVHD/GVL mismatch (Table 2).
VHD and FcRIIa Polymorphism
Of 73 patients, 55 patients (75%) developed acute
VHD at a median of 17 days (range, 11-63 days)
fter transplantation; 25 patients had grade I, 28 pa-
ients had grade II, 1 patient had grade III, and 1
atient had grade IV acute GVHD. The cumulative
ate was 75% at day 100.
Clinical risk factors besides the pro-GVHD mis-
atch introduced into the Kaplan-Meier analysis and
he Cox regression model were recipient age, disease
tatus, type of allogeneic transplantation, CMV serosta-
us, and sex match.
In univariate analysis at day 100, the pro-GVHD
Donor
-R/H131 FcRlla-H/H131 Total
3 4* 20
17 7* 30
14 8 23
34 19 73FcRlla
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FcRIIa as Target for Acute GVHD in Allogeneic SCT
Bismatch was signiﬁcantly associated with an in-
reased risk for acute GVHD (grades I-IV: no pro-
VHD mismatch, 67%; pro-GVHD mismatch, 94%;
 .023; Figure 1). The type of allogeneic transplan-
ation showed a nonsigniﬁcant association with acute
VHD (allogeneic BMT, 89%; allogeneic MUD,
6%; allogeneic PBSCT, 65%; P  .075; Table 3). In
ultivariate analysis, only the pro-GVHD mismatch
P  .026) was associated with an increased risk for
cute GVHD (Table 4).
Sixty-nine patients survived more than 100 days
nd could be analyzed for chronic GVHD. Sixteen
atients (23%) developed chronic GVHD. Chronic
VHD was graded as limited in 10 patients (14%)
nd as extensive in 6 patients (9%). At 2 years, the
umulative incidence rate was 13%. In addition to the
reviously mentioned covariates, acute GVHD was
ncluded in the analysis.
In univariate analysis, none of the factors was
ssociated with an increased risk for chronic GVHD.
n multivariate analysis, high-risk patients (P  .03)
ere associated with an increased risk for chronic
VHD (Table 4).
VL and FcRIIa Polymorphism
The 2-year relapse incidence of all patients was
1%. Covariates used for the analyses besides the
ro-GVHD mismatch were recipient age, disease sta-
us, type of allogeneic transplantation, CMV serosta-
us, sex match, and acute and chronic GVHD.
In univariate analysis at 2 years, high-risk disease
tatus (standard risk, 26%; high risk, 69%; P  .0005)
nd the absence of chronic GVHD (none, 51%; limited/
xtensive, 13%; P  .01) were associated with an in-
reased risk of relapse (Table 3). The relapse incidence
or all patients was not inﬂuenced by the pro-GVL
igure 1. Probability of grade I to IV acute graft-versus-host
isease in 73 AML patients with or without the FcRIIa pro-uVHD mismatch.
B&MTismatch (P  1.0), although we found a reduced re-
apse incidence of 13% in patients with the pro-GVL
ismatch and a relapse incidence of 30% in patients
ithout the pro-GVL mismatch (P  .32) in the stan-
ard-risk group of AML patients. Multivariate analysis
howed again that high-risk disease status (P .001) and
he absence of chronic GVHD (P  .018) increased the
isk for relapse (Table 4).
verall Survival
The 5-year estimate of overall survival for the entire
opulation was 51%. In addition to the previously men-
ioned covariates, relapse and date of transplantation
ere included in the analyses. Univariate analysis at 5
ears showed standard-risk disease status (standard risk,
0%; high risk, 40%; P .01), the occurrence of chronic
VHD (none, 45%; limited/extensive, 81%; P  .014),
nd the absence of relapse (yes, 24%; no, 69%; P 
0001) to be signiﬁcantly associated with better overall
urvival. Acute GVHD (no, 81%; yes, 47%; P  .08)
howed a nonsigniﬁcant association (Table 3). In multi-
ariate analysis for overall survival, the absence of relapse
P  .005) was the only factor associated with better
verall survival
Table 4).
ISCUSSION
This study shows that an FcRIIa allotype mismatch
ay be a target for acute GVHD after partial T cell–
epleted allogeneic SCT. We observed a statistically
igniﬁcant difference for acute GVHD in patients with
he pro-GVHDmismatch compared with patients with-
ut this mismatch both in univariate and multivariate
nalyses (P  .023 and P  .026, respectively). The
ro-GVHD mismatch was the only factor that was in-
ependently associated with the occurrence of acute
VHD; no other signiﬁcant risk factor was found.
hronic GVHD was not inﬂuenced by the pro-GVHD
ismatch. After multivariate analysis, only high-risk pa-
ients had a signiﬁcantly higher risk for chronic GVHD.
isease status and chronic GVHD seemed to be signif-
cant risk factors for relapse in multivariate analysis. Re-
apse was a signiﬁcant risk factor for overall survival. The
ro-GVHD/GVLmismatch had no signiﬁcant effect on
elapse or overall survival.
In this study, we used acute GVHD grade 0 versus
cute GVHD grades I to IV as a positive biologic reac-
ion in humans to see whether the pro-GVHD mis-
atch was a candidate for mHa. All skin erythemas,
ncluding clinically suspected grade I acute GVHD,
ere diagnosed by skin biopsy. Differences could be
scertained between a medication reaction and acute
VHD after analysis by specialized pathologists. For
ore relevant clinical information, it might be better to
se grade II and higher, but in our group of patients,
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2nly 2 patients developed grade III or IV; therefore, we
ombined grades I to IV. The relatively low grades of
cute GVHD in the study population are caused by our
-cell depletion procedure [21]. Almost half of our pa-
ients with acute GVHD developed grade I GVHD.
urthermore, we did not ﬁnd any effect of the pro-
VHD mismatch on the severity of acute GVHD
grade I versus grades II-IV; P  .79).
In genotypically HLA-identical SCT, antihost al-
oreactive donor T cells are, by deﬁnition, directed
gainst mHa presented by host cells [4-6]. Previous
tudies have shown that mHa are central in the inci-
ence and severity of GVHD [7-10,25]. An mHa is of
linical interest only if it is immunogenic and has a
elatively frequent distribution in the population.
cRIIa is certainly immunogenic [17,18,26] and has
frequent distribution. Twenty-ﬁve percent of our
atients had allotype mismatches for FcRIIa with a
ro-GVHD/GVL mismatch. This makes the FcRIIa
olymorphism an mHa of clinical interest as a target
or GVHD and GVL in allogeneic SCT.
The genetically determined polymorphism for
cRIIa speciﬁes 2 allelic variants with crucial differ-
nces in the extracellular ligand binding domain. A
oint mutation (G into A) results in an arginine (R131)
r histidine (H131) at amino acid position 131 in the
econd immunoglobulin-like domain of FcRIIa and
reatly affects the afﬁnity and speciﬁcity of the receptor
11-13]. In our study, 68% (50 of 73) of the Caucasian
able 3. Inﬂuence of the Pro-GVHD/GVL Mismatch and Clinical Ris
nd Relapse Incidence by Univariate Analysis
Outcome (No. Events)
cute GVHD (grade I-IV) at day 100 (n  55)
hronic GVHD (limited/extensive) (n  16 of 69 at risk)
elapse incidence at 2 y (n  25)
urvival at 5 y (n  30 deaths)
llo indicates allogeneic.atients and 74% (54 of 73) of the Caucasian donors i
10xpressed the FcRIIa-R/R131 or -R/H131 allotypes,
nd these numbers correspond with frequencies found
or Caucasians in other studies [14-16].
FcRIIa is expressed on all subtypes of granulo-
ytic precursor cells and also on Langerhans cells,
endritic cells, and endothelial cells [11]. In this study,
e found a clear association between FcRIIa mis-
atches and acute GVHD. The pro-GVHD mis-
atch was the only single signiﬁcant risk factor for
cute GVHD in univariate and multivariate analyses.
o effect was found on the occurrence of chronic
VHD. This might be caused by the small number of
atients in our study, the small number of patients
ho developed chronic GVHD, or the different
echanisms of immune attack between acute and
hronic GVHD [27].
The FcRIIa molecule is well expressed on leukemic
ells. A previous study in patients with AML showed the
resence of FcRIIa in 95% of the AML cells [28]. We
onﬁrmed the expression of FcRIIa on myeloid blasts
n 86% of patients with AML [29]. However, we could
ot ﬁnd the possible effect of the pro-GVLmismatch on
elapse. This might be due to the relatively small number
f patients, including some with a relatively short follow-
p, or to the group of high-risk AML patients also
ncluded in this study.When performing a subanalysis in
he standard-risk group of AML patients, we found a
rend toward a reduced relapse incidence in the pro-
VL mismatch group, with a relapse incidence of 13%
s on the Incidence of Acute and Chronic GVHD, Overall Survival,
Variable Incidence P Value
o-GVHD mismatch .023
Yes 94%
No 67%
pe of transplantation .075
Allo-BMT 89%
Allo-MUD 56%
Allo-PBSCT 65%
ne
sease status .0005
High risk 69%
Standard risk 26%
ronic GVHD .01
Limited/extensive 13%
No 51%
sease status .01
High risk 40%
Standard risk 60%
lapse <.0001
Yes 24%
No 69%
ute GVHD .08
Grade 0 81%
Grade I-IV 47%
ronic GVHD .014
Limited/extensive 81%
No 45%k Factor
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Bapse incidence of 30% in the patients without the pro-
VL mismatch (P  .32). Conversely, we did observe a
igniﬁcantly lower relapse incidence in patients with
hronic GVHD. Because the pro-GVHD mismatch it-
elf had no effect on the occurrence of chronic GVHD,
ts absence as a potential target for GVL is in line with
hese observations. This could lead to the suggestion
hat for FcRIIa in partially T cell–depleted SCT,
VHD and GVL are 2 different reactions [3]. A larger
ohort of patients with longer follow-up is mandatory to
onﬁrm whether there is also a pro-GVL effect by the
cRIIa allotypemismatch. In the future, we also plan to
erform T-cell studies to demonstrate a functional im-
unologic response to target cells that express the poly-
orphic antigen. As far as we know, this is the ﬁrst study
n the polymorphism switch of the FcRIIa gene. In this
tudy we cannot rule out other confounding genetic
ffects, such as the gene polymorphisms of interleukin
0, tumor necrosis factor, and interferon gamma. Future
tudies will review whether the FcRIIa gene polymor-
hism is as important as these other gene polymor-
hisms.
We postulate that allotypes of FcRIIa on den-
ritic cells, Langerhans cells, and endothelial cells of
he recipient may be candidate mHa for acute GVHD.
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